Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer

Urology

Volumn 52, Issue 2, 1998, Pages 252-256

  Sartor, Oliver ^a   Weinberger, Maribeth ^b   Moore, Andrea ^b   Li, Ailing ^b   Figg, William D ^b  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN DERIVATIVE; MEGESTROL ACETATE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DYSPNEA; HUMAN; MALE; MYOPATHY; ORAL DRUG ADMINISTRATION; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; HUMANS; MALE; MULTIVARIATE ANALYSIS; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT FAILURE;

EID: 0032145378     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00149-6     Document Type: Article

References (21)

1. Miller G.M., Hinman F. Jr. Cortisone treatment in advanced carcinoma of the prostate. J Urol. 72:1954;485-496.
2. Tannock I., Gospodarowicz M., Meakin W., et al. Treatment of metastatic prostate cancer with low-dose prednisone evaluation of pain and quality of life as pragmatic indices of response . J Clin Oncol. 7:1989;590-597.
3. Small E.J., Vogelzang N.J. Second-line hormonal therapy for advanced prostate cancer. J Clin Oncol. 15:1997;382-388.
4. Sartor O., Cooper M., Weinberger M., et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J Natl Cancer Inst. 86:1994;222-227.
5. Harland S.J., Duchesne G.M. Suramin and prostate cancer the role of hydrocortisone (letter) . Eur J Cancer. 28A:1992;1295.
6. Small E.J., Baron A.D., Fippin L., et al. Ketoconazole retains activity in advanced prostate cancer patients despite flutamide withdrawal. J Urol. 157:1997;1204-1207.
7. Eisenberger M.A., Reyno L.M., Jodrell D.I., et al. Suramin, an active drug for prostate cancer interim observations in a phase I trial . J Natl Cancer Inst. 85:1993;611-621.
8. Stein C.A., La Rocca R.V., Thomas R., et al. Suramin an anticancer drug with a unique mechanism of action . J Clin Oncol. 7:1989;499-508.
9. Sella A., Kilbourn R., Amato R., et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol. 12:1994;683-688.
10. Scher H., Kelly W.K. Flutamide withdrawal syndrome its impact on clinical trials in hormone-refractory prostate cancer . J Clin Oncol. 11:1993;1566-1572.
11. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer a Canadian randomized trial with palliative end points . J Clin Oncol. 14:1996;1756-1764.
12. Dawson N.A., Cooper M.R., Figg W.D., et al. Activity of suramin in hormone-refractory prostate cancer when hydrocortisone treatment and flutamide withdrawal are removed as potentially confounding variables. Cancer. 76:1995;453-462.
13. Kelly W.K., Curley T., Leibertz C., et al. Prospective evaluation of hydrocortisone and suramin in hormonally relapsed prostate cancer. J Clin Oncol. 13:1995;2208-2213.
14. Fossa S.D., Paus E. Reduction of serum prostate-specific antigen during endocrine or cytotoxic treatment of hormone-resistant cancer of the prostate. Eur Urol. 26:1994;29-34.
15. Datta S.N., Thomas K., Mathews P.N. Is prednisolone as good as flutamide in hormone refractory metastatic carcinoma of the prostate? J Urol. 158:1997;175-177.
16. Storlie J.A., Buckner J.C., Wiseman G.A., et al. Prostate-specific antigen levels and clinical response to low-dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer. 76:1995;96-100.
17. Harvey W.H., Bretton P.R. Response of hormone-resistant prostate cancer to dexamethasone by weekly intravenous injection improvement in performance status, bone pain, and reduction in prostate specific antigen . Proc Am Soc Clin Oncol. 13:1994;255.
18. Cox D.R. Regression models and life tables. J R Stat Soc Ser B. 34:1972;187-202.
19. Montgomery B.T., Young C.Y., Bilhartz D.L., et al. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate. 21:1992;63-73.
20. Takatsuka D., Uchida N., Yamamoto R., et al. Enhancement by androgen of the angiogenic ability of androgen-responsive Shionogi carcinoma 115. Anticancer Res. 12:1992;2001-2004.
21. Kelly W.K., Scher H.I., Mazumdar M., et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol. 11:1993;607-615.